Lepodisiran · ACCLAIM-CTA
ACCLAIM-CTA measures coronary plaque imaging. It is separate from ACCLAIM-Lp(a) hard cardiovascular outcomes; neither an Lp(a) reduction nor another drug's CV result settles it. lepodisiran — phase 3 study in Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a). NCT07613294 measures Percent Change from Baseline in Noncalcified Plaque (NCP) Volume (Baseline, Week 104). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Long-horizon imaging study — date unconfirmed
Potential outcome market
Will lepodisiran meet the prespecified primary endpoint in NCT07613294 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.